Le Lézard
Classified in: Environment, Health
Subjects: ENI, ENP, ANW, CFG

Health Canada launches consultation on use of imidacloprid pesticide


Some uses of this neonicotinoid are proposed for phase out to protect bees and other pollinators

OTTAWA, May 31, 2018 /CNW/ - Canadians care about how the use of pesticides impacts the environment. The Government of Canada relies on scientific evidence to evaluate pesticides so that they are used safely and do not threaten human health or the environment. With that in mind, the Government of Canada is consulting Canadians on its latest proposal to protect bees and other pollinators from exposure to imidacloprid, a neonicotinoid pesticide.

Health Canada's scientific assessment of imidacloprid looked at the effects of this pesticide on pollinators such as honey bees, bumble bees and solitary bees. The assessment found that there are some uses of imidacloprid that may pose a risk to bees. The Department is therefore proposing significant restrictions on the use of imidacloprid products to protect bees and other pollinators. These proposed restrictions include the cancellation of some uses, restrictions on the timing of use, and new product labels.

Consultations on this proposed decision will be open to the public for 90 days. Comments received during this consultation will be considered along with input from previous consultations, including separate restrictions that were proposed in 2016 to protect aquatic insects. We expect to publish a final decision on the overall use of imidacloprid in Canada in December 2018.

Health Canada's primary objective in regulating pesticides is to protect the health of Canadians and the environment. All pesticides must undergo a rigorous science-based review before being approved for sale in Canada.

Quick Facts

Related Products
Backgrounder: Proposed Re-evaluation Decision: Imidacloprid ? Pollinator (Bee) Assessment

Associated Links
PRVD2018-12: Proposed Re-evaluation Decision on Imidacloprid (Pollinator Assessment) 
PRVD2016-20: Proposed Re-evaluation Decision on Imidacloprid 
December 2017 Update on Neonicotinoid Pesticides
PRVD2017-23: Proposed Re-evaluation Decision on Clothianidin and Its Associated End-use Products: Pollinator Re-evaluation 
PRVD2017-24: Proposed Re-evaluation Decision on Thiamethoxam and Its Associated End-use Products: Pollinator Re-evaluation 
Update on Bee Incident Reports 2012-2016

 

SOURCE Health Canada


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: